{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:56:00Z","timestamp":1791219360480,"version":"4.1.0"},"reference-count":157,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"unspecified","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["bmjmed"],"accepted":{"date-parts":[[2026,7,27]]},"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the effectiveness of drug treatments for the management of fibromyalgia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Systematic review and network meta-analysis of randomised trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources<\/jats:title>\n                    <jats:p>Medline, Embase, AMED (Allied and Complementary Medicine Database), PsycInfo, CINAHL, and Cochrane CENTRAL (Cochrane Central Register of Controlled Trials), from inception to 13 January 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Eligibility criteria for selecting studies<\/jats:title>\n                    <jats:p>Parallel, crossover, and cluster randomised trials that enrolled adults (aged \u226518 years) with fibromyalgia, according to any published diagnostic criteria or as diagnosed by a physician. Trials compared commercially available, investigational, or discontinued drug treatments with another drug, the same drug at a different dose or regimen, placebo, or standard care. Treatments also included select vitamins and supplements, such as melatonin, vitamin D, vitamin B6, and omega 3 fatty acids.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>151 eligible trials (32\u2009592 participants) were included in this systematic review. Compared with placebo or usual care, low certainty evidence suggested that sodium oxybate, selective noradrenaline (norepinephrine) reuptake inhibitors (NRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs), and gabapentinoids may increase the likelihood of patient reported meaningful improvement or recovery (risk difference 105 to 283 more per 1000\u2009patients). Based on scores from the fibromyalgia impact questionnaire, low certainty evidence further suggested that sodium oxybate (mean difference \u20138.81, 95%\u2009confidence interval (CI) \u201311.78 to \u20135.84) and selective serotonin reuptake inhibitors (SSRIs) (mean difference \u20138.02, 95%\u2009CI \u201313.40 to \u20132.64) may reduce fibromyalgia symptoms, whereas tricyclic antidepressants, sodium oxybate, and gabapentinoids may improve sleep quality. No drug showed pooled effects on pain, physical health or mental health that met or exceeded a threshold for clinical importance. For sodium oxybate, selective NRIs, SNRIs, and cyclobenzaprine, responder analyses indicated that a potentially important proportion of patients achieved a reduction in pain of at least 30% (risk difference 111 to 202 more per 1000\u2009patients). In addition, no drug increased the risk of discontinuing treatment or serious adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This systematic review and network meta-analysis provides low certainty evidence that sodium oxybate, selective NRIs, SNRIs, gabapentinoids, tricyclic antidepressants, and SSRIs may provide typically small benefits in select outcomes for people with fibromyalgia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>PROSPERO CRD42012003291.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjmed-2026-002902","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:05:13Z","timestamp":1791216313000},"page":"e002902","source":"Crossref","is-referenced-by-count":0,"title":["Drug treatments for fibromyalgia: systematic review and network meta-analysis of randomised trials"],"prefix":"10.1136","volume":"5","author":[{"given":"Dena","family":"Zeraatkar","sequence":"first","affiliation":[{"name":"Department of Anaesthesia, McMaster University, Hamilton, Ontario, Canada"},{"name":"Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Pedro","family":"Lima","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1271-8509","authenticated-orcid":false,"given":"Sarah","family":"Kirsh","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ling","sequence":"additional","affiliation":[{"name":"Department of Anaesthesia, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamed","family":"Movahed","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haotao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Anaesthesia, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Huynh","sequence":"additional","affiliation":[{"name":"Department of Anaesthesia, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanvir","family":"Jassal","sequence":"additional","affiliation":[{"name":"Department of Anaesthesia, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Walch","sequence":"additional","affiliation":[{"name":"Department of Anaesthesia, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahsa","family":"Raji Lahiji","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Pitre","sequence":"additional","affiliation":[{"name":"Division of Respirology, Department of Medicine, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel J","family":"Couban","sequence":"additional","affiliation":[{"name":"Department of Anaesthesia, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9422-5232","authenticated-orcid":false,"given":"Behnam","family":"Sadeghirad","sequence":"additional","affiliation":[{"name":"Department of Anaesthesia, McMaster University, Hamilton, Ontario, Canada"},{"name":"Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Agoritsas","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada"},{"name":"Department of Rheumatology, Geneva University Hospitals, Geneva, Switzerland"},{"name":"MAGIC Evidence Ecosystem Foundation, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0178-8712","authenticated-orcid":false,"given":"Jason W","family":"Busse","sequence":"additional","affiliation":[{"name":"Department of Anaesthesia, McMaster University, Hamilton, Ontario, Canada"},{"name":"Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"2026100509050750000_5.1.e002902.1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22083891","article-title":"Fibromyalgia: pathogenesis, mechanisms, diagnosis and treatment options update","volume":"22","author":"Siracusa","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026100509050750000_5.1.e002902.2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2619-16.2016"},{"key":"2026100509050750000_5.1.e002902.3","doi-asserted-by":"crossref","first-page":"110624","DOI":"10.1016\/j.jpsychores.2021.110624","article-title":"Central sensitisation in chronic fatigue syndrome and fibromyalgia; a case control study","volume":"150","author":"Bourke","year":"2021","journal-title":"J Psychosom Res"},{"key":"2026100509050750000_5.1.e002902.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbre.2017.01.005"},{"key":"2026100509050750000_5.1.e002902.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2008.12.003"},{"key":"2026100509050750000_5.1.e002902.6","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/art.38905","article-title":"The prevalence of fibromyalgia in the general population: a comparison of the American College of Rheumatology 1990, 2010, and modified 2010 classification criteria","volume":"67","author":"Jones","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2026100509050750000_5.1.e002902.7","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-017-3725-2"},{"key":"2026100509050750000_5.1.e002902.8","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1055\/s-0038-1676090","article-title":"Fibromyalgia and irritable bowel syndrome in female pelvic pain","volume":"36","author":"Johnson","year":"2018","journal-title":"Semin Reprod Med"},{"key":"2026100509050750000_5.1.e002902.9","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-134-9_Part_2-200105011-00011"},{"key":"2026100509050750000_5.1.e002902.10","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3390\/jcm11030771","article-title":"Pain burden in post-COVID-19 syndrome following mild COVID-19 infection","volume":"11","author":"Bileviciute-Ljungar","year":"2022","journal-title":"JCM"},{"key":"2026100509050750000_5.1.e002902.11","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1111\/j.1526-4637.2012.01475.x","article-title":"Burden of illness and treatment patterns for patients with fibromyalgia","volume":"13","author":"Robinson","year":"2012","journal-title":"Pain Med"},{"key":"2026100509050750000_5.1.e002902.12","first-page":"154","article-title":"A study of standard care in fibromyalgia syndrome: a favorable outcome","volume":"30","author":"Fitzcharles","year":"2003","journal-title":"J Rheumatol"},{"key":"2026100509050750000_5.1.e002902.13","first-page":"1171","article-title":"Work and disability status of persons with fibromyalgia","volume":"24","author":"Wolfe","year":"1997","journal-title":"J Rheumatol"},{"key":"2026100509050750000_5.1.e002902.14","first-page":"270","article-title":"Fibromyalgia versus rheumatoid arthritis: a longitudinal comparison of the quality of life","volume":"22","author":"Martinez","year":"1995","journal-title":"J Rheumatol"},{"key":"2026100509050750000_5.1.e002902.15","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110026"},{"key":"2026100509050750000_5.1.e002902.16","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/918216"},{"key":"2026100509050750000_5.1.e002902.17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209724"},{"key":"2026100509050750000_5.1.e002902.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2018.10.008"},{"key":"2026100509050750000_5.1.e002902.19","unstructured":"Forte ML , Butler M , Andrade KE , et al . Table 1, fda-approved drugs for the treatment of fibromyalgia. In: Treatments for fibromyalgia in adult subgroups. Rockville (MD): Agency for Healthcare Research and Quality (US), 2015."},{"key":"2026100509050750000_5.1.e002902.20","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s11916-024-01277-9","article-title":"Pharmacological treatment of fibromyalgia syndrome: a practice-based review","volume":"28","author":"Giorgi","year":"2024","journal-title":"Curr Pain Headache Rep"},{"key":"2026100509050750000_5.1.e002902.21","doi-asserted-by":"crossref","unstructured":"Moore RA , Derry S , Aldington D . Amitriptyline for neuropathic pain in adults. Cochrane Database Syst Rev 2019. doi:10.1002\/14651858.CD007076.pub3","DOI":"10.1002\/14651858.CD007076.pub3"},{"key":"2026100509050750000_5.1.e002902.22","doi-asserted-by":"publisher","DOI":"10.1002\/art.20076"},{"key":"2026100509050750000_5.1.e002902.23","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000039109","article-title":"Physicians\u2019 knowledge, attitudes, and practices regarding fibromyalgia: a systematic review and meta-analysis of cross-sectional studies","volume":"103","author":"Agarwal","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"2026100509050750000_5.1.e002902.24","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.12939","article-title":"Comparison of amitriptyline and US Food and Drug Administration-approved treatments for fibromyalgia: a systematic review and network meta-analysis","volume":"5","author":"Farag","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026100509050750000_5.1.e002902.25","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1007\/s10067-022-06129-8","article-title":"Comparative efficacy of amitriptyline, duloxetine and pregabalin for treating fibromyalgia in adults: an overview with network meta-analysis","volume":"41","author":"Alberti","year":"2022","journal-title":"Clin Rheumatol"},{"key":"2026100509050750000_5.1.e002902.26","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1001\/jamainternmed.2020.5651","article-title":"Association of therapies with reduced pain and improved quality of life in patients with fibromyalgia: a systematic review and meta-analysis","volume":"181","author":"Mascarenhas","year":"2021","journal-title":"JAMA Intern Med"},{"key":"2026100509050750000_5.1.e002902.27","doi-asserted-by":"crossref","DOI":"10.1186\/s13018-023-03995-z","article-title":"Duloxetine for fibromyalgia syndrome: a systematic review and meta-analysis","volume":"18","author":"Migliorini","year":"2023","journal-title":"J Orthop Surg Res"},{"key":"2026100509050750000_5.1.e002902.28","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1093\/rheumatology\/keae707","article-title":"Effectiveness of pharmacological therapies for fibromyalgia syndrome in adults: an overview of Cochrane Reviews","volume":"64","author":"Moore","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2026100509050750000_5.1.e002902.29","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/17512433.2022.2044792","article-title":"Pharmacological management of fibromyalgia: a Bayesian network meta-analysis","volume":"15","author":"Migliorini","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2026100509050750000_5.1.e002902.30","doi-asserted-by":"publisher","DOI":"10.1136\/rapm-2024-105776"},{"key":"2026100509050750000_5.1.e002902.31","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.13455","article-title":"Tramadol for management of fibromyalgia pain and symptoms: Systematic review","volume":"74","author":"da Rocha","year":"2020","journal-title":"Int J Clin Pract"},{"key":"2026100509050750000_5.1.e002902.32","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/acr.25505","article-title":"Effects of pharmacologic and nonpharmacologic interventions for the management of sleep problems in people with fibromyalgia: systematic review and network meta-analysis of randomized controlled trials","volume":"77","author":"Hudson","year":"2025","journal-title":"Arthritis Care Res"},{"key":"2026100509050750000_5.1.e002902.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2003.08.001"},{"key":"2026100509050750000_5.1.e002902.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2007.09.002"},{"key":"2026100509050750000_5.1.e002902.35","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.141440"},{"key":"2026100509050750000_5.1.e002902.36","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.k4817","article-title":"When continuous outcomes are measured using different scales: guide for meta-analysis and interpretation","volume":"364","author":"Murad","year":"2019","journal-title":"BMJ"},{"key":"2026100509050750000_5.1.e002902.37","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD"},{"key":"2026100509050750000_5.1.e002902.38","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f2914","article-title":"Demystifying trial networks and network meta-analysis","volume":"346","author":"Mills","year":"2013","journal-title":"BMJ"},{"key":"2026100509050750000_5.1.e002902.39","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.i5191","article-title":"Introduction to BMJ rapid recommendations","volume":"354","author":"Siemieniuk","year":"2016","journal-title":"BMJ"},{"key":"2026100509050750000_5.1.e002902.40","doi-asserted-by":"crossref","unstructured":"World Health Organization . World health organization model list of essential medicines \u2013 23rd list. In: Executive summary of the report of the 24th WHO Expert Committee on the Selection and Use of Essential Medicines. Geneva, 2023.","DOI":"10.1530\/ey.19.13.1"},{"key":"2026100509050750000_5.1.e002902.41","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1993.tb26343.x"},{"key":"2026100509050750000_5.1.e002902.42","unstructured":"Higgins JPT , Thomas J , Chandler J , et al . Cochrane handbook for systematic reviews of interventions version 6.5 (updated august 2024) [Cochrane]. 2024. Available: www.training.cochrane.org\/handbook"},{"key":"2026100509050750000_5.1.e002902.43","doi-asserted-by":"crossref","unstructured":"Forbes C , Greenwood H , Carter M , et al . Automation of duplicate record detection for systematic reviews: Deduplicator. Syst Rev 2024;13. doi:10.1186\/s13643-024-02619-9","DOI":"10.1186\/s13643-024-02619-9"},{"key":"2026100509050750000_5.1.e002902.44","unstructured":"The Retraction Watch Database. New York: The Center for Scientific Integrity, 2018. Available: http:\/\/retractiondatabase.org"},{"key":"2026100509050750000_5.1.e002902.45","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110277"},{"key":"2026100509050750000_5.1.e002902.46","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090368"},{"key":"2026100509050750000_5.1.e002902.47","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090367"},{"key":"2026100509050750000_5.1.e002902.48","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000146","article-title":"Real-life assessment of the validity of patient global impression of change in fibromyalgia","volume":"1","author":"Rampakakis","year":"2015","journal-title":"RMD Open"},{"key":"2026100509050750000_5.1.e002902.49","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199206000-00002"},{"key":"2026100509050750000_5.1.e002902.50","first-page":"728","article-title":"The fibromyalgia impact questionnaire: development and validation","volume":"18","author":"Burckhardt","year":"1991","journal-title":"J Rheumatol"},{"key":"2026100509050750000_5.1.e002902.51","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170098"},{"key":"2026100509050750000_5.1.e002902.52","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2147\/PPA.S4633","article-title":"Predictors of premature discontinuation of treatment in multiple disease states","volume":"3","author":"Nantz","year":"2009","journal-title":"Patient Prefer Adherence"},{"key":"2026100509050750000_5.1.e002902.53","doi-asserted-by":"publisher","DOI":"10.1002\/sim.5519"},{"key":"2026100509050750000_5.1.e002902.54","first-page":"e31","article-title":"Have last-observation-carried-forward analyses caused us to favour more toxic dementia therapies over less toxic alternatives? A systematic review","volume":"3","author":"Molnar","year":"2009","journal-title":"Open Med"},{"key":"2026100509050750000_5.1.e002902.55","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jrsm.1349","article-title":"Dealing with missing outcome data in meta-analysis","volume":"11","author":"Mavridis","year":"2020","journal-title":"Res Synth Methods"},{"key":"2026100509050750000_5.1.e002902.56","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1093\/aje\/kwaf284","article-title":"Resurrecting complete-case analysis: a defense","volume":"195","author":"Mathur","year":"2026","journal-title":"Am J Epidemiol"},{"key":"2026100509050750000_5.1.e002902.57","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2026100509050750000_5.1.e002902.58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2021.09.021"},{"key":"2026100509050750000_5.1.e002902.59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2020.06.015"},{"key":"2026100509050750000_5.1.e002902.60","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l6802","article-title":"Impact of blinding on estimated treatment effects in randomised clinical trials: meta-epidemiological study","volume":"368","author":"Moustgaard","year":"2020","journal-title":"BMJ"},{"key":"2026100509050750000_5.1.e002902.61","doi-asserted-by":"publisher","DOI":"10.1111\/anae.15263"},{"key":"2026100509050750000_5.1.e002902.62","doi-asserted-by":"publisher","DOI":"10.1111\/anae.15297"},{"key":"2026100509050750000_5.1.e002902.63","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-084164","article-title":"Protocol for the development of a tool (INSPECT-SR) to identify problematic randomised controlled trials in systematic reviews of health interventions","volume":"14","author":"Wilkinson","year":"2024","journal-title":"BMJ Open"},{"key":"2026100509050750000_5.1.e002902.64","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/jrsm.1316","article-title":"A comparison of heterogeneity variance estimators in simulated random\u2010effects meta\u2010analyses","volume":"10","author":"Langan","year":"2019","journal-title":"Res Synth Methods"},{"key":"2026100509050750000_5.1.e002902.65","doi-asserted-by":"publisher","DOI":"10.1136\/bmjebm-2022-111928"},{"key":"2026100509050750000_5.1.e002902.66","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/jrsm.1397","article-title":"A comparison of Bayesian and frequentist methods in random-effects network meta-analysis of binary data","volume":"11","author":"Seide","year":"2020","journal-title":"Res Synth Methods"},{"key":"2026100509050750000_5.1.e002902.67","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-020-0917-3","article-title":"A simulation study to compare different estimation approaches for network meta-analysis and corresponding methods to evaluate the consistency assumption","volume":"20","author":"Kiefer","year":"2020","journal-title":"BMC Med Res Methodol"},{"key":"2026100509050750000_5.1.e002902.68","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X13481110"},{"key":"2026100509050750000_5.1.e002902.69","unstructured":"Carlin BP , Hong H , Shamliyan TA , et al . AHRQ methods for effective health care. In: Case study comparing Bayesian and frequentist approaches for multiple treatment comparisons. Rockville (MD): Agency for Healthcare Research and Quality (US), 2013."},{"key":"2026100509050750000_5.1.e002902.70","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/465281"},{"key":"2026100509050750000_5.1.e002902.71","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2010.233"},{"key":"2026100509050750000_5.1.e002902.72","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"2026100509050750000_5.1.e002902.73","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/jrsm.46","article-title":"Pooling health\u2010related quality of life outcomes in meta\u2010analysis\u2014a tutorial and review of methods for enhancing interpretability","volume":"2","author":"Thorlund","year":"2011","journal-title":"Res Synth Methods"},{"key":"2026100509050750000_5.1.e002902.74","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2018.11.025"},{"key":"2026100509050750000_5.1.e002902.75","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2023.06.010"},{"key":"2026100509050750000_5.1.e002902.76","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jrsm.1167","article-title":"Automated generation of node\u2010splitting models for assessment of inconsistency in network meta\u2010analysis","volume":"7","author":"van Valkenhoef","year":"2016","journal-title":"Res Synth Methods"},{"key":"2026100509050750000_5.1.e002902.77","doi-asserted-by":"publisher","DOI":"10.1002\/sim.6188"},{"key":"2026100509050750000_5.1.e002902.78","doi-asserted-by":"crossref","unstructured":"Higgins JP , Thomas J , Chandler J , et al . Cochrane handbook for systematic reviews of interventions.2nd edn. Chichester (UK): John Wiley & Sons, 2019.","DOI":"10.1002\/9781119536604"},{"key":"2026100509050750000_5.1.e002902.79","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186"},{"key":"2026100509050750000_5.1.e002902.80","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2692"},{"key":"2026100509050750000_5.1.e002902.81","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-8-79"},{"key":"2026100509050750000_5.1.e002902.82","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2016.04.015"},{"key":"2026100509050750000_5.1.e002902.83","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"2026100509050750000_5.1.e002902.84","doi-asserted-by":"publisher","DOI":"10.1136\/ebmental-2019-300117"},{"key":"2026100509050750000_5.1.e002902.85","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v106.i02"},{"key":"2026100509050750000_5.1.e002902.86","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.200077"},{"key":"2026100509050750000_5.1.e002902.87","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2017.10.005"},{"key":"2026100509050750000_5.1.e002902.88","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g5630","article-title":"A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis","volume":"349","author":"Puhan","year":"2014","journal-title":"BMJ"},{"key":"2026100509050750000_5.1.e002902.89","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2022.07.014"},{"key":"2026100509050750000_5.1.e002902.90","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.m1714","article-title":"Evaluating the credibility of anchor based estimates of minimal important differences for patient reported outcomes: instrument development and reliability study","volume":"369","author":"Devji","year":"2020","journal-title":"BMJ"},{"key":"2026100509050750000_5.1.e002902.91","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2020.11.024"},{"key":"2026100509050750000_5.1.e002902.92","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.081090"},{"key":"2026100509050750000_5.1.e002902.93","doi-asserted-by":"crossref","first-page":"E1260","DOI":"10.1097\/BRS.0000000000002684","article-title":"Minimum clinically important difference in SF-36 scores for use in degenerative cervical myelopathy","volume":"43","author":"Badhiwala","year":"2018","journal-title":"Spine"},{"key":"2026100509050750000_5.1.e002902.94","doi-asserted-by":"crossref","unstructured":"Fu V , Weatherall M , McNaughton H . Estimating the minimal clinically important difference for the Physical Component Summary of the Short Form 36 for patients with stroke. J Int Med Res 2021;49. doi:10.1177\/03000605211067902","DOI":"10.1177\/03000605211067902"},{"key":"2026100509050750000_5.1.e002902.95","doi-asserted-by":"crossref","first-page":"E474","DOI":"10.1097\/BRS.0000000000001950","article-title":"Minimum clinically important difference and substantial clinical benefit in pain, functional, and quality of life scales in failed back surgery syndrome patients","volume":"42","author":"Park","year":"2017","journal-title":"Spine (Phila Pa 1976)"},{"key":"2026100509050750000_5.1.e002902.96","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1097\/BRS.0000000000002298","article-title":"Minimal clinically important difference in quality of life for patients with low back pain","volume":"42","author":"D\u00edaz-Arribas","year":"2017","journal-title":"Spine (Phila Pa 1976)"},{"key":"2026100509050750000_5.1.e002902.97","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2024.104559"},{"key":"2026100509050750000_5.1.e002902.98","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpain.2006.05.002"},{"key":"2026100509050750000_5.1.e002902.99","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2385"},{"key":"2026100509050750000_5.1.e002902.100","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2019.10.014"},{"key":"2026100509050750000_5.1.e002902.101","doi-asserted-by":"crossref","DOI":"10.1186\/2046-4053-2-18","article-title":"Systematic review and network meta-analysis of interventions for fibromyalgia: a protocol","volume":"2","author":"Busse","year":"2013","journal-title":"Syst Rev"},{"key":"2026100509050750000_5.1.e002902.102","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780330203"},{"key":"2026100509050750000_5.1.e002902.103","unstructured":"Lederman S, Sullivan G, inventors; Tonix Pharmaceuticals Holding Corp, assignee. Cyclobenzaprine treatment for fibromyalgia. Canada patent CA3204202A1. 2021."},{"key":"2026100509050750000_5.1.e002902.104","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.101025"},{"key":"2026100509050750000_5.1.e002902.105","unstructured":"European phase III, multicentre, double-blind, randomised, monotherapy, 12-month study of milnacipran for the treatment of the fibromyalgia syndrome - FMS European long-term study. 2006. Available: https:\/\/trialsearchwhoint\/Trial2aspx?TrialID=EUCTR2006-001230-41-FI"},{"key":"2026100509050750000_5.1.e002902.106","doi-asserted-by":"crossref","DOI":"10.3389\/fpain.2024.1497111","article-title":"Cannabis combined with oxycodone for pain relief in fibromyalgia pain: a randomized clinical self-titration trial with focus on adverse events","volume":"5","author":"van Dam","year":"2024","journal-title":"Front Pain Res (Lausanne)"},{"key":"2026100509050750000_5.1.e002902.107","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1526-4637.2009.00755.x","article-title":"Durability of therapeutic response to milnacipran treatment for fibromyalgia: results of a randomized, double-blind, monotherapy 6-month extension study","volume":"11","author":"Goldenberg","year":"2010","journal-title":"Pain Med"},{"key":"2026100509050750000_5.1.e002902.108","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/acr.22111","article-title":"Twice daily versus once nightly dosing of pregabalin for fibromyalgia: a double-blind randomized clinical trial of efficacy and safety","volume":"66","author":"Nasser","year":"2014","journal-title":"Arthritis Care Res"},{"key":"2026100509050750000_5.1.e002902.109","doi-asserted-by":"publisher","DOI":"10.1177\/030006059302100202"},{"key":"2026100509050750000_5.1.e002902.110","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1007\/s00213-013-3422-0","article-title":"Quetiapine extended-release (Seroquel-XR) versus amitriptyline monotherapy for treating patients with fibromyalgia: a 16-week, randomized, flexible-dose, open-label trial","volume":"231","author":"Calandre","year":"2014","journal-title":"Psychopharmacology (Berl)"},{"key":"2026100509050750000_5.1.e002902.111","first-page":"47","article-title":"The investigation effects of pregabalin and duloxetine treatment according to personality characteristics groupe with fibromyalgia patients","volume":"18","author":"Celebi","year":"2016","journal-title":"Duzce Med J"},{"key":"2026100509050750000_5.1.e002902.112","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40199-019-00257-4","article-title":"Comparing duloxetine and pregabalin for treatment of pain and depression in women with fibromyalgia: an open-label randomized clinical trial","volume":"27","author":"Bidari","year":"2019","journal-title":"DARU J Pharm Sci"},{"key":"2026100509050750000_5.1.e002902.113","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s13075-015-0718-y","article-title":"A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients","volume":"17","author":"Murakami","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2026100509050750000_5.1.e002902.114","unstructured":"A Study of Duloxetine in Fibromyalgia, 2012. Available: https:\/\/clinicaltrialsgov\/show\/NCT01552057"},{"key":"2026100509050750000_5.1.e002902.115","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinthera.2013.07.026","article-title":"OC027\u2014Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized double-blind placebo-controlled trial","volume":"35","author":"Matthey","year":"2013","journal-title":"Clin Ther"},{"key":"2026100509050750000_5.1.e002902.116","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2008.11.009"},{"key":"2026100509050750000_5.1.e002902.117","doi-asserted-by":"crossref","DOI":"10.1186\/1477-7525-7-64","article-title":"Evaluation of the impact of fibromyalgia on patients\u2019 sleep and the content validity of two sleep scales","volume":"7","author":"Martin","year":"2009","journal-title":"Health Qual Life Outcomes"},{"key":"2026100509050750000_5.1.e002902.118","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1781(89)90047-4"},{"key":"2026100509050750000_5.1.e002902.119","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-043276","article-title":"Internal consistency and factor structure of Jenkins Sleep Scale: cross-sectional cohort study among 80\u2009000 adults","volume":"11","author":"Juhola","year":"2021","journal-title":"BMJ Open"},{"key":"2026100509050750000_5.1.e002902.120","doi-asserted-by":"publisher","DOI":"10.1007\/BF00434408"},{"key":"2026100509050750000_5.1.e002902.121","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/33.6.781"},{"key":"2026100509050750000_5.1.e002902.122","first-page":"185","article-title":"Measuring health status: a new tool for clinicians and epidemiologists","volume":"35","author":"Hunt","year":"1985","journal-title":"J R Coll Gen Pract"},{"key":"2026100509050750000_5.1.e002902.123","unstructured":"Safety and tolerability study comparing sodium oxybate given as an oral solution to a single-blinded combination of oral tablets plus oral solution in subjects with fibromyalgia, 2008. Available: https:\/\/clinicaltrialsgov\/show\/NCT00803023"},{"key":"2026100509050750000_5.1.e002902.124","doi-asserted-by":"crossref","first-page":"111392","DOI":"10.1016\/j.jclinepi.2024.111392","article-title":"High certainty evidence is stable and trustworthy, whereas evidence of moderate or lower certainty may be equally prone to being unstable","volume":"171","author":"Djulbegovic","year":"2024","journal-title":"J Clin Epidemiol"},{"key":"2026100509050750000_5.1.e002902.125","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s11136-016-1414-3","article-title":"When global rating of change contradicts observed change: Examining appraisal processes underlying paradoxical responses over time","volume":"26","author":"Schwartz","year":"2017","journal-title":"Qual Life Res"},{"key":"2026100509050750000_5.1.e002902.126","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000146corr1","article-title":"Correction","volume":"1","year":"2015","journal-title":"RMD Open"},{"key":"2026100509050750000_5.1.e002902.127","unstructured":"Xyrem (sodium oxybate) [prescribing information]. Palo Alto, CA: Jazz Pharmaceuticals Inc, 2025."},{"key":"2026100509050750000_5.1.e002902.128","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200418"},{"key":"2026100509050750000_5.1.e002902.129","unstructured":"A safety and efficacy study of xyrem\u00ae (sodium oxybate) to treat fibromyalgia. 2007. Available: https:\/\/clinicaltrialsgov\/show\/NCT00423813"},{"key":"2026100509050750000_5.1.e002902.130","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.091041"},{"key":"2026100509050750000_5.1.e002902.131","doi-asserted-by":"publisher","DOI":"10.1002\/art.24142"},{"key":"2026100509050750000_5.1.e002902.132","unstructured":"Trial Comparing the Effects of Xyrem (Sodium Oxybate) With Placebo for the Treatment of Fibromyalgia, 2004. Available: https:\/\/clinicaltrialsgov\/show\/NCT00087555"},{"key":"2026100509050750000_5.1.e002902.133","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0700-x"},{"key":"2026100509050750000_5.1.e002902.134","unstructured":"U.S. Food and Drug Administration . Neurontin, Gralise, Horizant (gabapentin) and Lyrica, Lyrica CR (pregabalin): drug safety communication\u2014serious breathing problems. 2019. Available: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/neurontin-gralise-horizant-gabapentin-and-lyrica-lyrica-cr-pregabalin-drug"},{"key":"2026100509050750000_5.1.e002902.135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002396","article-title":"Gabapentin, opioids, and the risk of opioid-related death: a population-based nested case-control study","volume":"14","author":"Gomes","year":"2017","journal-title":"PLoS Med"},{"key":"2026100509050750000_5.1.e002902.136","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.410"},{"key":"2026100509050750000_5.1.e002902.137","unstructured":"U.S. Food and Drug Administration . Statistical review and evaluation: antiepileptic drugs and suicidality. 2008."},{"key":"2026100509050750000_5.1.e002902.138","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20140"},{"key":"2026100509050750000_5.1.e002902.139","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2016.08.012"},{"key":"2026100509050750000_5.1.e002902.140","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100594"},{"key":"2026100509050750000_5.1.e002902.141","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1093\/pm\/pnx271","article-title":"A survey of physicians\u2019 knowledge and adherence to the diagnostic criteria for fibromyalgia","volume":"19","author":"Kumbhare","year":"2018","journal-title":"Pain Med"},{"key":"2026100509050750000_5.1.e002902.142","doi-asserted-by":"crossref","unstructured":"Wigers SH , Veier\u00f8d MB , Mengshoel AM , et al . Healthcare experiences of fibromyalgia patients and their associations with satisfaction and pain relief: a patient survey. Scand J Pain 2024;24. doi:10.1515\/sjpain-2023-0141","DOI":"10.1515\/sjpain-2023-0141"},{"key":"2026100509050750000_5.1.e002902.143","first-page":"87","article-title":"Clinical trial on the efficacy of various therapeutic procedures for the relief of pain in patients with fibromyalgia","volume":"9","author":"Collazo","year":"2015","journal-title":"Rev Int Acupuntura"},{"key":"2026100509050750000_5.1.e002902.144","doi-asserted-by":"crossref","DOI":"10.1097\/PR9.0000000000001222","article-title":"Fibromyalgia: do I tackle you with pharmacological treatments?","volume":"10","author":"Perrot","year":"2025","journal-title":"PR9"},{"key":"2026100509050750000_5.1.e002902.145","unstructured":"A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia (AFFIRM), 2025. Available: https:\/\/wwwclinicaltrialsgov\/study\/NCT02436096"},{"key":"2026100509050750000_5.1.e002902.146","unstructured":"Metformin for fibromyalgia symptoms (inform trial). 2025. Available: https:\/\/clinicaltrialsgov\/study\/NCT05900466"},{"key":"2026100509050750000_5.1.e002902.147","unstructured":"Lidocaine Versus Magnesium Sulphate in Management of Myofascial Pain Dysfunction Syndrome, 2024. Available: https:\/\/clinicaltrialsgov\/study\/NCT06595017"},{"key":"2026100509050750000_5.1.e002902.148","unstructured":"A Clinical Study of ONO-1110 in Patients With Fibromyalgia, 2025. Available: https:\/\/clinicaltrialsgov\/study\/NCT06752590"},{"key":"2026100509050750000_5.1.e002902.149","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2015.11.018"},{"key":"2026100509050750000_5.1.e002902.150","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n2040","article-title":"Medical cannabis or cannabinoids for chronic pain: a clinical practice guideline","volume":"374","author":"Busse","year":"2021","journal-title":"BMJ"},{"key":"2026100509050750000_5.1.e002902.151","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000000679"},{"key":"2026100509050750000_5.1.e002902.152","unstructured":"Tonix Pharmaceuticals Holding Corp . Tonix Pharmaceuticals announces phase 3 RALLY study results for TNX-102 SL 5.6 mg for the management of fibromyalgia [Internet]. Chatham, NJ: Tonix Pharmaceuticals, 2022. Available: https:\/\/ir.tonixpharma.com\/news-events\/press-releases\/detail\/1304\/tonix-pharmaceuticals-announces-phase-3-rally-study-results"},{"key":"2026100509050750000_5.1.e002902.153","unstructured":"Sullivan G , Gendreau R , Gendreau J , et al . A phase 3 randomized, double-blind, placebo-controlled trial of bedtime sublingual cyclobenzaprine (TNX-102 SL) for the treatment of fibromyalgia (FM): evidence for a broad spectrum of activity on the FM syndrome [abstract]. Arthritis Rheumatol 2019;71."},{"key":"2026100509050750000_5.1.e002902.154","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.mayocp.2023.12.018","article-title":"A cross-sectional survey study of cannabis use for fibromyalgia symptom management","volume":"99","author":"Singla","year":"2024","journal-title":"Mayo Clin Proc"},{"key":"2026100509050750000_5.1.e002902.155","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S404651"},{"key":"2026100509050750000_5.1.e002902.156","doi-asserted-by":"crossref","first-page":"6317","DOI":"10.1111\/jan.16773","article-title":"The experience of stigma in people affected by fibromyalgia: a metasynthesis","volume":"81","author":"Colombo","year":"2025","journal-title":"J Adv Nurs"},{"key":"2026100509050750000_5.1.e002902.157","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1907805"}],"container-title":["BMJ Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjmed-2026-002902","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:05:27Z","timestamp":1791216327000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjmedicine.bmj.com\/lookup\/doi\/10.1136\/bmjmed-2026-002902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":157,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,10,5]]},"published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1136\/bmjmed-2026-002902"],"URL":"https:\/\/doi.org\/10.1136\/bmjmed-2026-002902","relation":{},"ISSN":["2754-0413"],"issn-type":[{"value":"2754-0413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]}}}